Clinical Trials on Sanfilippo Syndrome Type B in United Kingdom

Total 4127 results

Shire

Completed

Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)

Sanfilippo Syndrome Type B

United States, United Kingdom, Germany
University of Minnesota
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Completed

Neurobehavioral Phenotypes in MPS III

Hurler Syndrome | Sanfilippo Syndrome Type A | Sanfilippo Syndrome Type B

United States
Shire

Terminated

Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

Sanfilippo Syndrome

Netherlands, United Kingdom
Alexion Pharmaceuticals

Completed

A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB

MPS IIIB (Sanfilippo Syndrome)

Spain, Netherlands, United Kingdom, United States, Brazil
Alexion Pharmaceuticals

Terminated

A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously (CL01-T)

Mucopolysaccharidosis III, Type B (MPS IIIB) | Sanfilippo B

United Kingdom
Alexion Pharmaceuticals

Completed

Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging

MPS IIIB (Sanfilippo B Syndrome)

United Kingdom
Shire

Completed

A Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA)

Sanfilippo Syndrome Type A

United States
Phoenix Nest
National Institute of Neurological Disorders and Stroke (NINDS)

Enrolling by invitation

A Natural History Study of Sanfilippo Syndrome Type D (MPSIIID)

Sanfilippo Syndrome Type D

United States
Phoenix Nest
Aparito Ltd.; Vaincres Les Maladies Lysosomales; Association Sanfilippo Sud

Not yet recruiting

Natural History Study of Participants With Sanfilippo Syndrome Type IIIC (MPSIIIC)

Sanfilippo Syndrome Type C

United States, France
Alexion Pharmaceuticals

Terminated

Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB

MPS IIIB (Sanfilippo B Syndrome)

Spain, United States, Brazil, United Kingdom, Portugal, Italy
Swedish Orphan Biovitrum

Completed

A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients

Sanfilippo Syndrome Type A (MPS IIIA)

United States, Turkey
Swedish Orphan Biovitrum

Completed

A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA Patients

Sanfilippo Syndrome Type A (MPS IIIA)

United States, Germany, Turkey
King's College Hospital NHS Trust

Terminated

Pilot Study of Unrelated Cord Blood Transplantation

Lymphoma, Non-Hodgkin | Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Hodgkin Disease | Chronic Lymphocytic Leukemia | Leukemia, Lymphoblastic, Acute

United Kingdom
University Hospital Southampton NHS Foundation...
Hoffmann-La Roche

Terminated

Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy (ARGO)

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United Kingdom
Ultragenyx Pharmaceutical Inc
Abeona Therapeutics, Inc

Active, not recruiting

Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH

Mucopolysaccharidosis III | Sanfilippo Syndrome | MPS IIIA | Sanfilippo A

United States, Australia, Spain
University College, London

Completed

Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation (COBALT)

Diffuse Large B-Cell Lymphoma

United Kingdom
Royal Marsden NHS Foundation Trust
Celgene Corporation

Active, not recruiting

Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND) (LEGEND)

Diffuse Large B-Cell Lymphoma

United Kingdom
Hoffmann-La Roche

Completed

Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma

United Kingdom
Ultragenyx Pharmaceutical Inc
Abeona Therapeutics, Inc

Terminated

Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease

Mucopolysaccharidosis III | Sanfilippo Syndrome | MPS IIIA | Sanfilippo A

United States, Spain, Australia
Royal Marsden NHS Foundation Trust
Hoffmann-La Roche

Terminated

R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma

B-cell Lymphoma | Non-Hodgkin's Lymphoma

United Kingdom
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC; Mundipharma-EDO GmbH

Withdrawn

A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL

Relapsed or Refractory Diffuse Large B-cell Lymphoma

United Kingdom
University of Southampton
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (P+R-ICE)

Diffuse Large B Cell Lymphoma

United Kingdom
University College, London
Novartis Pharmaceuticals

Active, not recruiting

RadiothErapy priMIng for CAR-T (REMIT)

Diffuse Large B Cell Lymphoma

United Kingdom
Oxford University Hospitals NHS Trust
University of Manchester; The Christie NHS Foundation Trust; Early Phase Cancer...

Completed

AZD1152 in Diffuse Large B-cell Lymphoma

Lymphoma

United Kingdom
University College, London

Completed

Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Lymphoma

United Kingdom
Shire

Terminated

An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.

Sanfilippo Syndrome | Mucopolysaccharidosis (MPS)

United States, United Kingdom, Spain, Germany, France, Italy, Netherlands
GlaxoSmithKline

Completed

Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant

Lymphoma, Large-Cell, Diffuse

United Kingdom
University Hospital Southampton NHS Foundation...
Cancer Research UK; The Christie NHS Foundation Trust; Celldex Therapeutics; Oxford... and other collaborators

Active, not recruiting

A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma (RiVa)

B Cell Lymphoma

United Kingdom
King's College Hospital NHS Trust

Terminated

Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin (FB-ATG)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United Kingdom
Shire

Completed

Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease

Sanfilippo Syndrome

United States, Spain, United Kingdom, Argentina, France, Germany, Italy, Netherlands
Pfizer
Medivation, Inc.

Completed

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

Acute Myeloid Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome

United Kingdom, United States
University College London Hospitals

Completed

CAR T Cell Therapy Related Cardiovascular Outcomes (CARTCO)

Cardiovascular Diseases | Diffuse Large B Cell Lymphoma | Cardiotoxicity | B-cell Acute Lymphoblastic Leukemia | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | B-cell Lymphoma Refractory | Cardiovascular Complication | B-cell Lymphoma Recurrent

United Kingdom
Onxeo

Completed

A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL

B-cell Chronic Lymphocytic Leukemia

United Kingdom
Cancer Research UK

Withdrawn

Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

Lymphoma

United Kingdom
Acerta Pharma BV

Active, not recruiting

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Small Lymphocytic Lymphoma | Richter's Syndrome

United States, United Kingdom, Italy
University of Birmingham
AstraZeneca; Cancer Research UK; Bloodwise

Completed

An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (TORCH)

Diffuse Large B-Cell Lymphoma

United Kingdom
University Hospital Southampton NHS Foundation...

Completed

A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL) (ACCEPT)

Non Hodgkin Lymphoma

United Kingdom
King's College Hospital NHS Trust

Unknown

Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy (PRO-DLI)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United Kingdom
University College, London

Recruiting

Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 (ALLCAR19)

Leukemia, Lymphoblastic, Acute, Lymphoma

United Kingdom
AstraZeneca

Completed

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Myelomonocytic Leukemia | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | High Risk Myelodysplastic Syndrome | Small Lymphocytic Lymphoma | B-cell Non-Hodgkin Lymphoma | Richter's Syndrome | T-cell Non-Hodgkin Lymphoma | Relapsed or Refractory...

United Kingdom, Germany, Netherlands
Medical Research Council

Completed

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia

Myelodysplastic Syndromes | Leukemia

United Kingdom
Epizyme, Inc.

Completed

Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors

Follicular Lymphoma | Marginal Zone Lymphoma | Advanced Solid Tumors | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal Lymphoma

United Kingdom
M.D. Anderson Cancer Center

Recruiting

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

B-Cell Lymphoma | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML)

United States
Acrotech Biopharma Inc.

Completed

Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma

United Kingdom, United States
Autolus Limited

Recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

United Kingdom
University College, London

Completed

Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) (LenD)

Chronic Lymphocytic Leukemia

United Kingdom
Acerta Pharma BV

Active, not recruiting

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)

United States, United Kingdom
King's College Hospital NHS Trust

Completed

CLL Empirical Antibiotic Regimen (CLEAR)

Chronic Lymphocytic Leukaemia (CLL)

United Kingdom
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Unknown

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

B-cell Non Hodgkin Lymphoma | Mature B-cell Leukemia Burkitt-type

Belgium, France, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain, China
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Treatment of Mature B-cell Lymphoma/Leukaemia

B-Cell Lymphoma

France, United Kingdom, United States

Clinical Trials on Sanfilippo Syndrome Type B in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations